U.S. markets closed
  • S&P Futures

    3,832.75
    +13.50 (+0.35%)
     
  • Dow Futures

    31,896.00
    +120.00 (+0.38%)
     
  • Nasdaq Futures

    12,360.50
    +63.25 (+0.51%)
     
  • Russell 2000 Futures

    2,208.50
    +7.70 (+0.35%)
     
  • Crude Oil

    65.36
    +0.31 (+0.48%)
     
  • Gold

    1,681.60
    +3.60 (+0.21%)
     
  • Silver

    25.22
    -0.05 (-0.21%)
     
  • EUR/USD

    1.1851
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.5960
    +0.0420 (+2.70%)
     
  • Vix

    25.47
    +0.81 (+3.28%)
     
  • GBP/USD

    1.3828
    +0.0006 (+0.05%)
     
  • USD/JPY

    109.1780
    +0.2770 (+0.25%)
     
  • BTC-USD

    53,293.23
    +1,552.38 (+3.00%)
     
  • CMC Crypto 200

    1,076.71
    +52.51 (+5.13%)
     
  • FTSE 100

    6,719.13
    +88.61 (+1.34%)
     
  • Nikkei 225

    28,726.67
    -16.58 (-0.06%)
     

Bronstein, Gewirtz & Grossman, LLC Notifies Liquidia Corporation (LQDA) Investors of Investigation

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / January 4, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Liquidia Corporation ("Liquidia" or "the Company") (NASDAQ:LQDA). Investors who purchased Liquidia securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/lqda.

The investigation concerns whether Liquidia and certain of its officers and/or directors have violated federal securities laws.

On November 25, 2020, Liquidia revealed that the U.S. Food and Drug Administration ("FDA") had issued a complete response letter ("CRL") for its New Drug Application ("NDA") for LIQ861 (treprostinil), inhalation powder for the treatment of pulmonary arterial hypertension ("PAH"). Liquidia said that "[i]n the CRL, the FDA stated that it is unable to approve the NDA at this time," citing "the need for additional information and clarification on chemistry, manufacturing and controls (CMC) data pertaining to the drug product and device biocompatibility." Following this news, Liquidia stock dropped over 5% to close at $2.94 per share on November 25, 2020.

If you are aware of any facts relating to this investigation, or purchased Liquidia shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/lqda. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/622866/Bronstein-Gewirtz-Grossman-LLC-Notifies-Liquidia-Corporation-LQDA-Investors-of-Investigation